Inventor · disambiguated record
Ingmar Hoerr
Also filed as: HOERR INGMAR
21 granted patents·51 pending applications·827 citations·filing 2003–2024
97Inventor score
Top patents by PatentIndex Score
72 records- 0199US11078247B2RNA encoding a therapeutic proteinCUREVAC AG·Filed 2017·Granted Aug 3, 2021·57 cites·18 claims
- 0299US9655955B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted May 23, 2017·42 cites·20 claims
- 0399US9463228B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Oct 11, 2016·28 cites·20 claims
- 0499US9439956B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Sep 13, 2016·29 cites·19 claims
- 0599US9433669B2Application of mRNA for use as a therapeutic against tumor diseasesCUREVAC AG·Filed 2015·Granted Sep 6, 2016·29 cites·20 claims
- 0699US9433670B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Sep 6, 2016·29 cites·20 claims
- 0798US11135312B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2014·Granted Oct 5, 2021·35 cites·16 claims
- 0898US10568972B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2016·Granted Feb 25, 2020·35 cites·23 claims
- 0998US9155788B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC GMBH·Filed 2014·Granted Oct 13, 2015·64 cites·20 claims
- 1098US8217016B2Application of mRNA for use as a therapeutic agent for tumorous diseasesHOERR INGMAR·Filed 2004·Granted Jul 10, 2012·195 cites·27 claims
- 1197US11369691B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2016·Granted Jun 28, 2022·11 cites·19 claims
- 1296US10434154B2Composition for treating prostate cancer (PCa)CUREVAC AG·Filed 2016·Granted Oct 8, 2019·29 cites·15 claims
- 1395US11596699B2RNA encoding an antibodyCureVac SE·Filed 2017·Granted Mar 7, 2023·11 cites·19 claims
- 1495US10188748B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsVON DER MUELBE FLORIAN·Filed 2003·Granted Jan 29, 2019·72 cites·32 claims
- 1595US9402887B2Composition for treating prostate cancer (PCa)CUREVAC AG·Filed 2013·Granted Aug 2, 2016·30 cites·48 claims
- 1694US9352028B2Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC)CUREVAC GMBH·Filed 2013·Granted May 31, 2016·33 cites·67 claims
- 1794US9226959B2Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvantKRAMPS THOMAS·Filed 2009·Granted Jan 5, 2016·57 cites·34 claims
- 1893US11421038B2RNA-coded antibodyHOERR INGMAR·Filed 2008·Granted Aug 23, 2022·12 cites·31 claims
- 1992US10441653B2Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvantHOERR INGMAR·Filed 2012·Granted Oct 15, 2019·29 cites·33 claims
- 2085US2022372158A1Rna-coded antibodyCUREVAC AG·Filed 2022·Application pending·0 cites
- 2183US2025084141A1Rna encoding a therapeutic proteinCureVac SE·Filed 2024·Application pending·0 cites
- 2276US12048738B2Composition for treating prostate cancer (PCa)CureVac SE·Filed 2019·Granted Jul 30, 2024·0 cites·18 claims
- 2376US2022401555A1NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANTCUREVAC AG·Filed 2022·Application pending·0 cites
- 2474US12227549B2RNA encoding a therapeutic proteinCureVac SE·Filed 2021·Granted Feb 18, 2025·0 cites·21 claims
- 2574US2022096616A1Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)CUREVAC AG·Filed 2021·Application pending·0 cites
- 2673US2019284260A1Rna-coded antibodyCUREVAC AG·Filed 2019·Application pending·0 cites
- 2773US2024075116A1Rna encoding a tumor antigenCureVac SE·Filed 2023·Application pending·0 cites
- 2872US2023293731A1Rna encoding an antibodyCureVac SE·Filed 2022·Application pending·0 cites
- 2971US2010291156A1Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)BARNER MARIJKE·Filed 2008·Application pending·0 cites
- 3070US2019134222A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC AG·Filed 2018·Application pending·0 cites
- 3169US2021308238A1Injection solution for rnaCUREVAC AG·Filed 2021·Application pending·0 cites
- 3268US2018256694A1Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)CUREVAC AG·Filed 2018·Application pending·0 cites
- 3367US2023181765A2PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCureVac SE·Filed 2016·Application pending·0 cites
- 3466US2017211068A1Immunostimulation by chemically modified rnaCUREVAC AG·Filed 2017·Application pending·0 cites
- 3565US2013195867A1Rna-coded antibodyCUREVAC GMBH·Filed 2012·Application pending·0 cites
- 3664US2009324584A1Nucleic Acid of Formula (I): GIXmGn, or (II): CIXmCn, in Particular as an Immune-Stimulating Agent/AdjuvantCUREVAC GMBH·Filed 2007·Application pending·0 cites
- 3764US2016152691A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3864US2016145346A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3964US2024285795A1Targets for rna therapeuticsCureVac SE·Filed 2021·Application pending·0 cites
- 4064US2016166692A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 4164US2016166690A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 4264US2010305196A1COMPOSITION FOR TREATING PROSTATE CANCER (PCa)CURE VAC GMBH·Filed 2008·Application pending·0 cites
- 4364US2016152706A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 4464US2016361438A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC AG·Filed 2016·Application pending·0 cites
- 4564US2016185840A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 4664US2016166691A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 4764US2016168254A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 4863US2008025944A1Combination Therapy for ImmunostimulationCURE VAC GMBH·Filed 2005·Application pending·0 cites
- 4963US2016317636A1Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)CUREVAC AG·Filed 2016·Application pending·0 cites
- 5063US2020085942A1NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANTCUREVAC AG·Filed 2019·Application pending·0 cites
Showing the top 50 of 72 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →